Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy
The trial is designed as a multi-center, open label Phase 2 trial that investigates the
efficacy and safety of Sym004 in subjects with squamous cell cancer of the head and neck
(SCCHN). Subjects included must have responded to previous anti-epidermal growth factor
receptor (anti-EGFR) monoclonal antibody-based therapy and subsequently become resistant to
that therapy. It is believed that Sym004 has the potential to induce tumor responses and
provide a superior treatment option to subjects with advanced SCCHN.
Symphogen was the sponsor for planning/conducting and reporting results for this trial.
Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer
Active, not recruiting
This is a Phase 2, open-label, 3-arm trial of two Sym004 doses (Arms A and B) and a control
group (Arm C) in subjects with metastatic colorectal cancer (mCRC) and acquired resistance
to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs).
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.